Ancheng Biotech

Ancheng Biotech is a biotechnology company focused on developing innovative gene editing therapies using its proprietary Glycosylase Base Editor (GBE) platform. Founded by leading scientists in the field of base editing, the company aims to treat genetic diseases and cancers through precise genomic modifications. Its primary focus is on hematological disorders, specifically targeting the correction or compensation of mutations in the hemoglobin subunit beta gene. Ancheng's technology is designed to offer higher precision and fewer off-target effects compared to first-generation CRISPR technologies. The company is headquartered in Shanghai and has received significant backing from major life science investors including Qiming Venture Partners and Lilly Asia Ventures. The GBE platform enables specific base conversions that were previously difficult to achieve, expanding the scope of treatable genetic conditions.